AstraZeneca Deepens Cancer Cell Therapy Portfolio with Neogene Buyout

AstraZeneca and Neogene Therapeutics have entered into a definitive acquisition agreement in which AstraZeneca will buy all outstanding equity in the smaller company.

The deal aims to advance T-cell receptor therapies against solid tumors, California-based Neogene announced Tuesday.